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Background
A successful monoclonal antibody (mAb) cell line devel-
opment requires efficient clone detection and screening.
Cloning by limiting dilution (LDC) is the traditional
method to isolate mAbs expressing clones [1]. Although
effective, LDC is time-consuming, with limited workflow
and therefore a critical step of cell line development. To
compare to LDC in terms of timelines and productiv-
ities for Rebmab100 mAb cell line development we have
implemented ClonePix FL (CP-FL), an automated sys-
tem for high throughput clone detection. The robotic
colony picker has the advantages of reducing the pro-
cess time and increasing the probability to isolate high-
producing clones. Moreover, we have combined these
two approaches with high throughput screening assays
for early detection of high productive clones.
Rebmab100 mAb targets Lewis-Y, a blood group-related
antigen expressed in over 70% of epithelial cancers, includ-
ing breast, colon, ovary and lung carcinomas. The murine
monoclonal 3S193 was generated in BALB/c mice by
immunization with Ley-expressing cells from the MCF-7
breast carcinoma cell line [2]. The humanized version of
anti- Ley 3S193 mAb was obtained by CDR-grafting
method [3]. The hu3S193 (Rebmab 100) mAb has potent
immune effector function (ADCC and CDC), is rapidly
internalized into Ley expressing cancer cells, and has been
shown to cause significant regressions in xenograft models
in preclinical studies, alone or in conjunction with isotope
and toxins [3,4]. Safety and desirable pharmacokinetic
profiles of Rebmab100 were demonstrated in a Phase I
clinical trial in patients with epithelial carcinomas [5] and
promising results have been obtained in a Phase II clinical
trial conducted in Brazil [6]. Very importantly, Rebmab100
was granted orphan-drug status by the FDA for ovary can-
cer. Aiming the next step of Rebmab100 mAb develop-
ment we generated a new Rebmab100 cell line that shows
stability and high productivity allowing its scale-up to later
clinical trials.
Materials and methods
Suspension Per.C6® cells (Crucell, Netherlands) were
transfected with a vector containing the genes coding for
heavy and light chains of Rebmab100 mAb. After selec-
tion by G418 the cells from the stable pool were cloned
by limiting dilution or plated in semi-solid medium
(Molecular Devices, USA) for ClonePix FL screening.
Cellular growth was assessed in plates, 96, 24 or 6-well
plates, either by CloneSelect Imager (Molecular Devices)
or Guava EasyCyte cytometer (Merck-Millipore). Antibody
titers were measured by Biacore T100 (GE Healthcare,
Sweden). The selected clones were transferred to T-flasks
and subsequently to shaker flasks (SF). Clones were ana-
lyzed in 50 mL and 200 mL SF fed-batch processes. The
stability study was performed for at least 50 generations in
continuous culture and also starting batch runs with cells
taken at different generations.
Results
Generation of Rebmab100 stable pool
The transfection of Per.C6® cells with a vector contain-
ing the genes coding for heavy and light chains of
Rebmab100 generated a stable pool through G418
selection.
Cloning using two different approaches
The stable pool was cloned by LDC in liquid medium at
0.5 cell/well in 50 96-well plates, resulting in 261 colo-
nies transferred to 24-well plates in 3-4 weeks after
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screening with the CloneSelect Imager. Concomitantly
the same pool was seeded at different concentrations
(300 to 2000 cells/mL) in semi-solid medium. The plates
were screened by light and fluorescence images about
ten days after seeding. A total of 845 colonies were
picked, from which 225 were transferred to 24-well
plates. At the transference step to 24-well plates, 261 out
of 4800 wells seeded in LDC were transferred while 225
colonies out of 845 colonies picked by CP-FL, representing
5.4% and 26.6% efficiency, respectively. Both approaches
followed sequential steps as transfer of the clones to
6-well plates, T-flasks and SF, selecting them at each step
for cell growth and productivity related to cell number.
Fed-batch experiments and stability study
Thirty-one clones adapted to suspension cultures were
assessed for productivity in fed-batch processes, being 15
originated from LDC and 16 from CP-FL. From the fed-
batch in 50 mL SF 12 clones presented titers ranging from
1.3 to 3.0 g/L (Figure 1A). Out of 31 clones, 10 were
selected for long-term stability study to determine growth
and productivity along the time required for mAb produc-
tion during a manufacturing process. The stability study
performed with 6 LDC and 4 CP-FL originated clones
ruled out 3 of them, two from LDC and one from CP-FL.
Seven clones showed genetic and cellular stability (data
not shown), 4 from LDC and 3 from CP-FL and were
further analyzed in fed-batch in 200 mL SF. In this study
we compared titers obtained after 2 weeks run for all
clones, with results ranging from 0.9 to 1.8 g/L to the
maximum productivity attained by each clone, obtained at
different lengths of culture (Figure 1B). Taken together
the data for cell growth, productivity, kinetic and func-
tional assays of the purified antibodies (data not shown),
mainly the immune-effector activity characteristically dis-
played by Rebmab100, we identified 4 lead clones, the first
and second originated by CP-FL screening. Final ranking
will be evaluated after bioreactor runs.
Conclusions
The CP-FL automated picking has the advantage of
being less labor-intensive and time-consuming, while
allowing the chance of picking clones that would not
grow isolated in LDC. Both CP-FL and LDC procedures
proved efficient for generating high productive and
stable cell clones. Overall productivity for individual
clones depends on specific productivity, cell density and
viability along time, allowing accumulation of the anti-
body. CP-FL clones reached maximum productivity at
an earlier stage (2 weeks) of the 200 mL SF fed-batch
experiment, which represents an advantage during the
manufacturing process.
The 4 lead clones will be submitted to bioreactor runs
to evaluate the most suitable clone for the Rebmab100
mAb to be used in clinical trials and eventually to go
under production.
Figure 1 Antibody titer measured by Biacore in SF fed-batch process (g/L). (A) 31 selected Rebmab100 clones measured on the last day of
a 50 mL SF fed-batch culture. (B) Maximum (grey bars) and 2 weeks (black bars) mAb productivity obtained in a 200 mL SF fed-batch culture for
the 7 stable Rebmab100 clones. The number above the grey bars indicates the day when maximum mAb productivity occurred.
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